PolarityTE

PolarityTE FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of PolarityTE (PTE) as of Nov 20, 2026 is 288.96 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 75.37 % — a change of 283.37% (higher).

FCF Conversion

288.96 %

YoY

283.37%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of PolarityTE is 2022 288.96 % . FCF Conversion Rate (FCF/EBITDA) of PolarityTE was 2021 75.37 % . It decreases by 283.37% higher compared to the previous year.

The PolarityTE FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
16.70 USD
Jan 1, 2016
7.71 USD
Jan 1, 2017
50.90 USD
Jan 1, 2018
47.99 USD
Jan 1, 2019
64.24 USD
Jan 1, 2020
91.22 USD
Jan 1, 2021
75.37 USD
Jan 1, 2022
288.96 USD
The PolarityTE FCF Conversion history
YEARFCF ConversionYoY
288.96 %+283.37%
75.37 %-17.38%
91.22 %+42.01%
64.24 %+33.86%
47.99 %-5.72%
50.90 %+560.43%
7.71 %-53.84%
16.70 %-36.73%
26.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PolarityTE Stock analysis

What does PolarityTE do? PolarityTE Inc is an innovative biotechnology company specializing in tissue and organ regeneration. The company's developed technologies allow for the creation of functional human tissue from a patient's own stem cells. The history of PolarityTE Inc began in Utah, USA, in 2016 when the company was founded by Dr. Denver Lough, a plastic surgeon. Dr. Lough and his team had a vision to build a new type of medical company that not only addresses the symptoms of diseases but also their root causes. PolarityTE Inc operates on a unique business model based on holistic and personalized medicine. The company utilizes state-of-the-art technologies to offer personalized therapies for patients suffering from a variety of conditions, including burns, wounds, scleroderma, and other tissue-damaging diseases. The different divisions of PolarityTE Inc include research and development of innovative drugs and technologies, clinical trials, product launches, and collaboration with experts from various fields to continuously improve the offering of products and services. The company offers a range of products made from regenerative tissue. The portfolio of PolarityTE Inc includes SkinTE, OsteoTE, and CartTe, each tailored to the specific needs of patients. SkinTE is a groundbreaking therapy for regenerating skin tissue, designed to accelerate the repair of damaged skin. The treatment aims to reduce the need for skin grafts and expedite the healing process of wounds and burns. OsteoTE is an innovative method for regenerating bone tissue, with the potential to revolutionize the treatment of bone fractures. The treatment utilizes the regenerative abilities of cells to promote the growth of healthy bone and expedite the healing of fractures. CartTe is a therapy for regenerating cartilage tissue, aiming to help people with joint pain and discomfort. The treatment harnesses the body's ability to repair damaged tissue, stimulating the growth of novel cartilage cells and improving joint function. Overall, PolarityTE Inc has the potential to revolutionize the treatment of wounds and diseases. The company focuses on personalized medicine based on individual patient needs and promotes the development of therapies targeting the root causes of diseases. PolarityTE is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolarityTE stock

FCF Conversion Rate (FCF/EBITDA) of PolarityTE is 288.96 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of PolarityTE changed from 75.37 % to 288.96 %, representing a 283.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) PolarityTE since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s PolarityTE with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PolarityTE

All Key Metrics — PolarityTE